Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.

Details

Serval ID
serval:BIB_186255E114C9
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
Journal
The European respiratory journal
Author(s)
Costantini A., Grynovska M., Lucibello F., Moisés J., Pagès F., Tsao M.S., Shepherd F.A., Bouchaab H., Garassino M., Aerts JGJV, Mazières J., Mondini M., Berghmans T., Meert A.P., Cadranel J.
ISSN
1399-3003 (Electronic)
ISSN-L
0903-1936
Publication state
Published
Issued date
02/2018
Peer-reviewed
Oui
Volume
51
Number
2
Pages
NA
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
In May 2017, the second European Respiratory Society research seminar of the Thoracic Oncology Assembly entitled "Immunotherapy, a new standard of care in thoracic malignancies?" was held in Paris, France. This seminar provided an opportunity to review the basis of antitumour immunity and to explain how immune checkpoint inhibitors (ICIs) work. The main therapeutic trials that have resulted in marketing authorisations for use of ICIs in lung cancer were reported. A particular focus was on the toxicity of these new molecules in relation to their immune-related adverse events. The need for biological selection, currently based on immunohistochemistry testing to identify the tumour expression of programmed death ligand (PD-L)1, was stressed, as well as the need to harmonise PD-L1 testing and techniques. Finally, sessions were dedicated to the combination of ICIs and radiotherapy and the place of ICIs in nonsmall cell lung cancer with oncogenic addictions. Finally, an important presentation was dedicated to the future of antitumour vaccination and of all ongoing trials in thoracic oncology.
Keywords
Antibodies, Monoclonal/therapeutic use, B7-H1 Antigen/analysis, Biomarkers, Tumor, Cancer Vaccines/immunology, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/therapy, Clinical Trials as Topic, Congresses as Topic, Europe, Humans, Immunohistochemistry, Immunotherapy/methods, Lung Neoplasms/therapy, Oncogenes, Paris, Patient Selection, Pulmonary Medicine/organization & administration, Pulmonary Medicine/standards, Societies, Medical, Standard of Care, Thoracic Neoplasms/immunology, Thoracic Neoplasms/therapy
Pubmed
Web of science
Create date
01/03/2018 21:21
Last modification date
20/08/2019 12:48
Usage data